Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with
ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to
evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s).
The study will be a multicenter study in the United States.